EUVIMEDEUVIMED entdecken
Crossref

GLP-1 Agonists Are Associated With a Significant Reduction in Breast Cancer Incidence in Women

Elizabeth S McDonald iD, Laura B Gillis, Peter E Gabriel iD, Kham M Xapakdy, Anthony J Young iD, Abigail G Doucette iD, Mitchell D Schnall, John B Buse iD, Etta D Pisano iD

JCO Oncology Practice · 2026

DOI: 10.1200/op-26-00485 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, 2026. Verfasst von Elizabeth S McDonald und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. Hauptthemen laut MEDLINE: Breast Neoplasms, Glucagon-Like Peptide-1 Receptor Agonists, Glucagon-Like Peptide 1. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Excess weight is a key modifiable risk factor for breast cancer. Glucagon-like peptide-1 receptor agonists (GLP-1) promote weight loss and improve metabolic health, but their effect on breast cancer risk remains unclear. METHODS We conducted a retrospective cohort study from January 1, 2022, to June 30, 2025, using electronic health records. We identified 217,624 unique women who underwent breast imaging; restricting to ages 45-80 years with a BMI ≥25 and a documented imaging outcome (n = 111,646; median age 61 years). The primary outcome was breast cancer detection. GLP-1 use was defined as a first prescription before the examination date and assessed in relation to race, ethnicity, age, and type 2 diabetes. To address potential confounding between these covariates and GLP-1 exposure, we performed one-to-one, case-control matching using propensity scores on the basis of age, race, ethnicity, highest BMI, breast density, and history of type 2 diabetes. The propensity matching to the GLP-1 use group was performed using the greedy nearest neighbor approach. RESULTS GLP-1 exposure was associated with a lower incidence of breast cancer (odds ratio [OR], 0.649 [95% CI, 0.569 to 0.741]; P < .0001). In the matched logistic regression (30,528 observations; 600 cancer cases), GLP-1 exposure was associated with a lower breast cancer incidence (OR, 0.695 [95% CI, 0.590 to 0.819]; P < .0001). CONCLUSION In this large observational study of women undergoing breast imaging at a major academic center and affiliated sites, GLP-1 treatment was associated with a lower incidence of breast cancer, independent of age, race, ethnicity, BMI, breast density, and diabetes. The findings support the need for prospective trials investigating GLP-1 agonists for breast cancer prevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide 1HumansFemaleMiddle AgedAgedRetrospective StudiesIncidenceAged, 80 and overDiabetes Mellitus, Type 2Risk FactorsCase-Control Studies

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide 1

Autor:innen und Institutionen

  • Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • American College of Radiology, Philadelphia, PA.
  • Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania.
  • Cancer Informatics Shared Resource, Abramson Cancer Center, University of Pennsylvania.
  • Penn Medicine, Philadelphia, PA.
  • Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC.

ORCID-Profile: Elizabeth S McDonald, Peter E Gabriel, Anthony J Young, Abigail G Doucette, John B Buse, Etta D Pisano

Zitieren

APA

McDonald, E. S., Gillis, L. B., Gabriel, P. E., Xapakdy, K. M., Young, A. J., Doucette, A. G., Schnall, M. D., Buse, J. B., & Pisano, E. D. (2026). GLP-1 Agonists Are Associated With a Significant Reduction in Breast Cancer Incidence in Women. JCO Oncology Practice. https://doi.org/10.1200/op-26-00485

Vancouver

McDonald ES, Gillis LB, Gabriel PE, Xapakdy KM, Young AJ, Doucette AG, et al. GLP-1 Agonists Are Associated With a Significant Reduction in Breast Cancer Incidence in Women. JCO Oncology Practice. 2026. doi:10.1200/op-26-00485

BibTeX
@article{McDonald2026,
  author = {McDonald, Elizabeth S and Gillis, Laura B and Gabriel, Peter E and Xapakdy, Kham M and Young, Anthony J and Doucette, Abigail G and Schnall, Mitchell D and Buse, John B and Pisano, Etta D},
  title = {GLP-1 Agonists Are Associated With a Significant Reduction in Breast Cancer Incidence in Women},
  journal = {JCO Oncology Practice},
  year = {2026},
  doi = {10.1200/op-26-00485}
}
Kostenlos starten →